{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:33:15Z","timestamp":1794555195042,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152746","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:57:07Z","timestamp":1746737827000},"page":"152746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-9934","authenticated-orcid":false,"given":"Iftach","family":"Sagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ItamarBen","family":"Shitrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Abuhasira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran Ben","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef S","family":"Haviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshrat","family":"Tayer-Shifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abu-Shakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Brav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitzan","family":"Burrack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semarthrit.2025.152746_bib0001","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MAJ.0b013e31827f4ee3","article-title":"Lupus nephritis and end-stage kidney disease","volume":"346","author":"Maroz","year":"2013","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152746_bib0002","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on Lupus Nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152746_bib0003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based Incidence and Prevalence of Systemic Lupus Erythematosus: the Michigan Lupus Epidemiology and Surveillance Program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152746_bib0004","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.autrev.2019.05.011","article-title":"The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study","volume":"18","author":"Mageau","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152746_bib0005","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1038\/s41598-018-24529-2","article-title":"Impact of diabetes mellitus on the risk of end-stage renal disease in patients with systemic Lupus Erythematosus","volume":"8","author":"Jiang","year":"2018","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.semarthrit.2025.152746_bib0006","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","article-title":"Long-term cardiovascular outcomes in systemic Lupus Erythematosus","volume":"77","author":"Yafasova","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152746_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152746_bib0008","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/jcm11061470","article-title":"SGLT2 inhibitors in type 2 diabetes mellitus and heart failure\u2014a concise review","volume":"11","author":"Keller","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152746_bib0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152746_bib0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/10408363.2021.1993439","article-title":"Cardiovascular benefit of SGLT2 inhibitors","volume":"59","author":"Mohebi","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152746_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152746_bib0012","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-med-042921-102135","article-title":"SGLT2 Inhibitors: the sweet success for kidneys","volume":"74","author":"Dharia","year":"2023","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152746_bib0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152746_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152746_bib0015","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/annrheumdis-2022-222512","article-title":"SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection","volume":"81","author":"Morales","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152746_bib0016","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3899\/jrheum.151221","article-title":"Incidence of systemic lupus erythematosus and lupus nephritis in Denmark: a nationwide cohort study","volume":"43","author":"Hermansen","year":"2016","journal-title":"J Rheumatol"},{"issue":"10391","key":"10.1016\/j.semarthrit.2025.152746_bib0017","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"The Lancet"},{"issue":"10188","key":"10.1016\/j.semarthrit.2025.152746_bib0018","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152746_bib0019","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"450","key":"10.1016\/j.semarthrit.2025.152746_bib0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/01621459.2000.10474233","article-title":"Combining propensity score matching with additional adjustments for prognostic covariates","volume":"95","author":"Rubin","year":"2000","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152746_bib0021","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/pan.2019.11","article-title":"Why propensity scores should not Be used for matching","volume":"27","author":"King","year":"2019","journal-title":"Polit Anal"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152746_bib0022","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/key335","article-title":"Temporal relationships between systemic lupus erythematosus and comorbidities","volume":"58","author":"Kuo","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152746_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102692","article-title":"Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population","volume":"123","author":"Hansen","year":"2021","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152746_bib0024","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/jcm10050998","article-title":"High comorbidity burden in patients with SLE: data from the community-based lupus registry of crete","volume":"10","author":"Gergianaki","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152746_bib0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3899\/jrheum.191064","article-title":"Advanced chronic kidney disease in Lupus nephritis: is dialysis inevitable?","volume":"47","author":"Tselios","year":"2020","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152746_bib0026","first-page":"1328","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"yu","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Supplement_1","key":"10.1016\/j.semarthrit.2025.152746_bib0027","doi-asserted-by":"crossref","first-page":"gfae069","DOI":"10.1093\/ndt\/gfae069.1281","article-title":"#1720 Insights from sodium-glucose transport 2 (SGLT2) inhibitors treatment in patients with systemic lupus erythematosus","volume":"39","author":"Kenis","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152746_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.16578","article-title":"Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic Lupus Erythematosus","volume":"7","author":"Yen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152746_bib0029","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.semarthrit.2025.152746_bib0030","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/dom.14489","article-title":"Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes","volume":"23","author":"Liu","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152746_bib0031","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","article-title":"Markers of kidney injury, inflammation, and fibrosis associated with Ertugliflozin in patients with CKD and diabetes","volume":"6","author":"Liu","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152746_bib0032","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2025.152746_bib0033","article-title":"1201 SGLT2 inhibitors modulate inflammation and germinal centers in lupus","volume":"11","author":"Rangel-Moreno","year":"2024","journal-title":"Lupus Sci Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152746_bib0034","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.autrev.2014.08.034","article-title":"Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:01:25Z","timestamp":1751594485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"alternative-id":["S0049017225001179"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152746","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152746"}}